Fiche publication


Date publication

décembre 2017

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre


Tous les auteurs :
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G,

Résumé

Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 (Y) resin microspheres in patients with hepatocellular carcinoma.

Mots clés

Administration, Oral, Adult, Aged, Antineoplastic Agents, administration & dosage, Brachytherapy, methods, Carcinoma, Hepatocellular, drug therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Liver Neoplasms, drug therapy, Male, Microspheres, Middle Aged, Neoplasm Invasiveness, pathology, Neoplasm Staging, Niacinamide, administration & dosage, Phenylurea Compounds, administration & dosage, Radiotherapy Dosage, Survival Analysis, Treatment Outcome, Yttrium Radioisotopes, therapeutic use

Référence

Lancet Oncol.. 2017 Dec;18(12):1624-1636